The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain

H Li, W Cao, Z Chen, DO Acheampong, H Jin… - Biomedicine & …, 2013 - Elsevier
Vascular endothelial growth factor (VEGF) is a key regulator of pathological angiogenesis
and vascular permeability and overexpressed by most solid tumors. VEGF receptor-2 …

Inhibition of angiogenesis by recombinant VEGF receptor fragments

D Ahmadvand, F Rahbarizadeh… - Laboratory …, 2010 - academic.oup.com
Background: Blocking vascular endothelial growth factor receptor (VEGFR) is a successful
approach for inhibiting vascular endothelial growth factor (VEGF) signaling. Small molecules …

Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice

RA Brekken, JP Overholser, VA Stastny… - Cancer research, 2000 - AACR
Vascular endothelial growth factor (VEGF) is a multifunctional angiogenic growth factor that
is a primary stimulant of the development and maintenance of a vascular network in …

[HTML][HTML] Recombinant human vascular endothelial growth factor receptor 1 effectively inhibits angiogenesis in vivo

J Wang, M Shi, Y Xi, L Gao… - Molecular …, 2015 - spandidos-publications.com
Vascular endothelial growth factor (VEGF) plays an important role in both physiological and
pathological angiogenesis. VEGF receptor‑1 (VEGFR‑1) acts as a decoy VEGF receptor that …

Expression of VEGFR2 Ligand Binding Domain in Pichia pink™ 4 Cells and Evaluation of Its Interactions with VEGF-A165 Receptor Binding Domain

Z Fathi, MMA Boojar, RH Sajedi, E Dehnavi… - Molecular …, 2024 - Springer
Vascular endothelial growth factor A 165 (VEGF-A 165) and VEGF receptor 2 (KDR) are
important mediators of angiogenesis. We aimed to express the soluble KDR ligand-binding …

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

L Witte, DJ Hicklin, Z Zhu, B Pytowski… - Cancer and Metastasis …, 1998 - Springer
Biological evidence suggests that interference with the function of the angiogenic growth
factor receptor VEGFR2 (flk1/KDR) is a particularly promising strategy to inhibit tumor …

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy

S Shinkaruk, M Bayle, G Lain… - … Medicinal Chemistry-Anti …, 2003 - ingentaconnect.com
Angiogenesis is a process of development and of growth of new capillary blood vessels from
pre-existing vessels. When pathological, it contributes to the development of numerous …

[HTML][HTML] A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its …

L Hetian, A Ping, S Shumei, L Xiaoying… - Journal of Biological …, 2002 - ASBMB
Vascular endothelial growth factor (VEGF), one of the most important angiogenic factors,
plays an essential role in both physiological and pathological angiogenesis. The VEGF …

In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment

B Kou, Y Li, L Zhang, G Zhu, X Wang, Y Li, J Xia… - … and molecular pathology, 2004 - Elsevier
The interaction of vessel endothelial cell growth factor (VEGF) and its receptors (flt-1, FLK-
1/KDR) regulates tumor angiogenesis. Therefore, blocking the binding of VEGF and the …

A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155

Y Ueda, T Yamagishi, K Samata, H Ikeya… - Molecular Cancer …, 2003 - AACR
Vascular endothelial growth factor (VEGF) plays a pivotal role in the processes of
angiogenesis, which is essential for the growth of solid tumors and their metastasis …